Vanda Pharmaceuticals Inc. (VNDA) SEC Filing 8-K Material Event for the period ending Friday, February 4, 2022

Vanda Pharmaceuticals Inc.

CIK: 1347178 Ticker: VNDA

View differences made from one to another to evaluate Vanda Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vanda Pharmaceuticals Inc..


Assess how Vanda Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vanda Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Vanda Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Ticker: VNDA
CIK: 1347178
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-027687
Submitted to the SEC: Fri Feb 04 2022 7:07:55 AM EST
Accepted by the SEC: Fri Feb 04 2022
Period: Friday, February 4, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: